La vendita allo scoperto per Akebia Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Akebia Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Akebia Therapeutics (NASDAQ:AKBA) Azioni, Report sulle vendite allo scoperto

Akebia Therapeutics

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Akebia Therapeutics Inc

AKBANK T/A/S GDR 144A by Akbank Turk Anonim Sirketi

Akbank TAS

AKBANK T/A/S S/ADR by Akbank Turk Anonim Sirketi

HC Wainwright &amp; Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and maintains $7.5 price target.

News

Price Target

Reiteration

Analyst Ratings

AKBA

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target

<a href="https://www.globenewswire.com/Tracker?data=7l57jPT7AZDn06CKZpFEvCZWIfVofhoCdY1ADg0wIzox9VuZpgQRe1PjoOSmOEVcGBL6lOiOros8Dh9aXF-XJoIVl6t6ZeONjLprU1SgmlU=">Akebia Therapeutics&#xAE;, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve XOANACYL&#xAE; (Ferric Citrate as Coordination Complex) for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).
Averoa, a renal-focused biopharmaceutical company, licensed the rights to develop and commercialize ferric citrate from Akebia in the European Economic Area and certain countries in Europe and the Middle East. Averoa recently announced the positive opinion from CHMP here: <a href="https://www.globenewswire.com/Tracker?data=YC3k_S4HYmByvgOHZ8KXr9C0l6cq2mm2kfWvZCIPt6Z_Lb_YAZuD_AN4OU8B8GfuKWmJWYc1ze_64nltBee9vEAkzlG0WPcS8tWwIQOgbg6vFL0aZwl9rFqnbqLk1eJ21wf7V3RWjz3kl4lrcqqsJ0FtpBJzHBRGq2fXfRng6WWEcZJcsByl-xY1MSoTfuiY4IfFo9KwQezWnnOVW2ZRKUgDbA9JFoMZh9bfpbTLWnRCZsioMOIoCuyDeRr2FdWMyD4-vYX-cKnW8l08ViedE5-LMOEdXv0Fd-LS6zelN-AJTu2nE1ZtTq8h_35h_TKX">https://averoa-pharma.org/wp-content/uploads/2025/04/20250402-AVA1014-Positive-opinion-EN-VF-2.04.2025.pdf</a>.
"We congratulate our partner Averoa on a positive step toward securing EMA approval for XOANACYL, and we will continue to support their efforts to deliver a treatment for complications of kidney disease to patients in Europe," said John P. Butler, Chief Executive Officer of Akebia.
The EC will review the CHMP recommendation, and a final decision is expected in approximately two months.

Biotech

General

Akebia Therapeutics Announces Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted A Positive Opinion Recommending The European Commission To Approve Xoanacyl For Treatment Of Concomitant Elevated Serum Phosphorous And Iron Deficiency In Adult Patients With Chronic Kidney Disease

Jefferies analyst Roger Song initiates coverage on Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy rating and announces Price Target of $6.

Initiation

Jefferies Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $6

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 226.4% to $1.73 during Thursday's regular session. The market value of their outstanding shares is at $19.9 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 205.28% to $1.56. The market value of their outstanding shares is at $9.1 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock moved upwards by 54.63% to $9.28. The company's market cap stands at $93.2 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock rose 31.36% to $2.22. The company's market cap stands at $1.6 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock moved upwards by 27.84% to $11.98. The company's market cap stands at $98.8 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>ARS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) stock moved upwards by 26.43% to $14.73. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock fell 38.8% to $0.29 during Thursday's regular session. The company's market cap stands at $17.3 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock decreased by 28.51% to $0.32. The market value of their outstanding shares is at $82.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares declined by 28.35% to $2.04. The company's market cap stands at $480.7 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 20.28% to $2.59. The company's market cap stands at $1.7 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares fell 18.76% to $1.43. The market value of their outstanding shares is at $46.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 17.1% to $1.94. The market value of their outstanding shares is at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADAP

BDRX

CRVO

ELEV

OPTN

PSTV

RMTI

SPRY

VERO

WINT

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday.
The Dow traded up 0.63% to 42,230.78 while the NASDAQ climbed 0.81% to 17,894.89. The S&amp;P 500 also rose, gaining, 0.61% to 5,710.13.
Check This Out: <a href="https://www.benzinga.com/25/03/44414809/tesla-to-450-here-are-10-top-analyst-forecasts-for-thursday">Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday</a>
Leading and Lagging Sectors Communication services shares rose by 1.4% on Thursday.
In trading on Thursday, consumer staples shares fell by 0.1%.
Top Headline
U.S. initial jobless claims increased by 2,000 to 223,000 during the second week of March, compared to market estimates of 224,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>ProAssurance Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) shares shot up 48% to $22.99 after the company announced it will be acquired by The Doctors Company for $25.00 per share in cash.</li>
<li>Shares of Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>)got a boost, surging 71% to $2.8950 after the company entered a license and supply agreement to become a sourcing partner for Evofem Biosciences for Evofem&#8217;s PHEXXI.</li>
<li>OptiNose, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) shares were also up, gaining 55% to $9.28 after Paratek Pharmaceuticals announced it will acquire the company in a deal worth $330 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Elevation Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) shares dropped 41% to $0.2798 after the company announced the discontinued development of EO-3021.</li>
<li>Shares of Benson Hill, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NASDAQ">BHIL</a>) were down 42% to $0.3755 after the company filed for Chapter 11 bankruptcy.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) was down, falling 30% to $1.9950 after the company announced the pricing of a $50 million offering of 25 million common shares at $2/share.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $68.00 while gold traded up 0.1% at $3,044.60.
Silver traded down 0.6% to $34.015 on Thursday, while copper fell 0.1% to $5.0930.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.47%, Germany's DAX 40 fell 1.43% and France's CAC 40 fell 0.86%. Spain's IBEX 35 Index fell 0.97%, while London's FTSE 100 slipped 0.15%.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with China's Shanghai Composite Index falling 0.51%, Hong Kong's Hang Seng Index dipped 2.23% and India's BSE Sensex gaining 1.19%.
Economics
<ul>
<li>U.S. existing home sales increased by 4.2% from the previous month to an annualized rate of 4.26 million homes in February.</li>
<li>The U.S. current account deficit shrank by 2.0% to $303.9 billion in the fourth quarter, versus a revised deficit of $310.3 billion in the third quarter.</li>
<li>U.S. initial jobless claims increased by 2,000 to 223,000 during the second week of March, compared to market estimates of 224,000.</li>
<li>The Philadelphia Fed Manufacturing Index fell to 12.5 in March from 18.1 in the previous month, versus market estimates of 8.5.</li>
<li>U.S. natural gas stocks increased 9 billion cubic feet in the week ending March 14, compared to market estimates of a 3 billion cubic feet gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44415297/how-to-earn-500-a-month-from-micron-technology-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Micron Technology Stock Ahead Of Q2 Earnings</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

BHIL

Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase

WIIM

Akebia Therapeutics shares are trading lower after the company announced the pricing of a $50 million offering of 25 million common shares at $2/share.

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday.
Shares of JOYY Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/YY/earnings">weak quarterly sales</a>.
JOYY reported quarterly earnings of $1.77 per share which beat the analyst consensus estimate of $1.18 per share. The company reported quarterly sales of $549.45 million which missed the analyst consensus estimate of $549.46 million by 0 percent. This is a 3.58 percent decrease over sales of $569.84 million the same period last year.
JOYY shares dipped 10.9% to $41.75 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares fell 26.2% to $2.09 in pre-market trading after the company priced its $50 million public offering of 25 million common shares at $2 per share.</li>
<li>Maze Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) fell 11.8% to $10.70 in today's pre-market trading.</li>
<li>GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) declined 7.2% to $11.01 in pre-market trading.</li>
<li>Enerflex Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFXT#NYSE">EFXT</a>) fell 7.1% to $7.00 in pre-market trading after the company reported that Marc Rossiter has stepped down as President, CEO, and Director.</li>
<li>ZTO Express (Cayman) Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) declined 5.8% to $20.49 in pre-market trading.</li>
<li>Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) fell 5.5% to $51.54 in pre-market trading after the company announced an offering of $1.35 of billion depository shares.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) fell 4.7% to $9.21 in pre-market trading.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 2.5% to $30.00 in pre-market trading.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks">Jim Cramer Says TJX Is &#8216;Terrific,&#8217; Recommends Buying These Stocks</a></li>
</ul>
Photo: zignal_88 on Shutterstock.com

Pre-Market Outlook

EFXT

GHRS

MAZE

MCHP

TIGR

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) shares moved upwards by 58.3% to $9.5 during Thursday's pre-market session. The market value of their outstanding shares is at $95.5 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock increased by 35.5% to $2.29. The company's market cap stands at $1.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock rose 20.99% to $0.62. The company's market cap stands at $3.6 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares moved upwards by 15.56% to $1.63. The company's market cap stands at $3.4 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares rose 13.01% to $0.85. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock rose 12.96% to $11.33. The market value of their outstanding shares is at $11.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) stock decreased by 23.9% to $2.16 during Thursday's pre-market session. The market value of their outstanding shares is at $510.2 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 16.67% to $1.95. The market value of their outstanding shares is at $1.3 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) shares fell 12.32% to $0.29. The company's market cap stands at $7.3 million. </li>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares decreased by 12.32% to $10.4. The market value of their outstanding shares is at $645.0 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares declined by 9.1% to $1.6. The company's market cap stands at $51.7 million. The company's, Q4 earnings came out today. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 9.07% to $0.35. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

AEON

MHUA

MSPR

TNFA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Shares of Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter <a href="https://in.benzinga.com/news/earnings/25/03/44406668/five-below-stock-moves-higher-on-q4-earnings-beat">guidance above estimates</a>.
Five Below reported adjusted earnings of $3.48 per share, beating market estimates of $3.38 per share. The company's sales came in at $1.391 billion versus expectations of $1.386 billion.
Five Below shares jumped 11.9% to $84.59 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>SAG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) gained 77.8% to $1.20 in pre-market trading after jumping 7% on Wednesday.</li>
<li>OptiNose, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) rose 59.3% to $9.56 in pre-market trading. Paratek Pharmaceuticals announced plans to acquire Optinose in a deal worth up to $330 million.</li>
<li>ProAssurance Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) gained 50.6% to $23.41 in pre-market trading after the company announced it will be acquired by The Doctors Company for $25.00 per share in cash.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) gained 40.3% to $0.1010 in pre-market. AGM Group Holdings announced the receipt of Nasdaq notification regarding minimum bid requirements.</li>
<li>DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) gained 28.7% to $0.4761 in pre-market trading after jumping 8% on Wednesday.</li>
<li>Emerson Radio Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSN#NYSE">MSN</a>) gained 27.2% to $0.56 in pre-market trading.</li>
<li>CIMG Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMG#NYSE">IMG</a>) gained 21.1% to $0.5812 in pre-market trading after the company announced its subsidiary signed a business cooperation intent agreement with Shanghai Huomao.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) rose 12.1% to $1.02 in pre-market trading.</li>
<li>Brookdale Senior Living Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) rose 8.1% to $6.60 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) fell 28.4% to $0.2196 in pre-market trading after the company announced a 1-for-20 reverse stock split.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares fell 26.2% to $2.09 in pre-market trading after the company priced its $50 million public offering of 25 million common shares at $2 per share.</li>
<li>Leishen Energy Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSE#NYSE">LSE</a>) fell 17.1% to $10.37 in pre-market trading after gaining around 66% on Wednesday. Leishen Energy recently reported FY24 financial results.</li>
<li>Riverview Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSB#NASDAQ">RVSB</a>) declined 13.2% to $4.66 in pre-market trading.</li>
<li>Benson Hill, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NASDAQ">BHIL</a>) dipped 13.2% to $0.56 in pre-market trading after dipping 15% on Wednesday.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares tumbled 13.2% to $0.0944 in pre-market trading. Virpax Pharmaceuticals shares fell 16% on Wednesday after the company announced a 1-for-25 reverse stock split.</li>
<li>Meihua International Medical Technologies Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) shares fell 12.3% to $0.2884 in pre-market trading.</li>
<li>Maze Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) fell 11.8% to $10.70 in today's pre-market trading.</li>
<li>JOYY Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) shares dipped 10.8% to $41.78 in pre-market trading following weak quarterly sales.</li>
<li>Enerflex Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFXT#NYSE">EFXT</a>) fell 7.1% to $7.00 in pre-market trading after the company reported that Marc Rossiter has stepped down as President, CEO, and Director.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks">Jim Cramer Says TJX Is &#8216;Terrific,&#8217; Recommends Buying These Stocks</a></li>
</ul>
Photo: Shutterstock

AGMH

DEVS

FIVE

IOBT

RVSB

VRPX

ZCAR

Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50.0 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on March 21, 2025, subject to the satisfaction of customary closing conditions

Reported Earlier, Akebia Therapeutics Prices $50M Public Offering Of 25M Common Shares At $2/Share

<h3>Gainers</h3>
<ul>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares rose 14.6% to $1.81 during Wednesday's after-market session. The company's market cap stands at $10.3 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock moved upwards by 11.0% to $2.22. The market value of their outstanding shares is at $2.4 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock rose 8.43% to $0.45. The market value of their outstanding shares is at $2.2 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares moved upwards by 6.36% to $0.62. The market value of their outstanding shares is at $52.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares rose 6.11% to $0.22. The market value of their outstanding shares is at $6.6 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares moved upwards by 5.7% to $0.38. The company's market cap stands at $38.1 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares fell 20.4% to $2.26 during Wednesday's after-market session. The market value of their outstanding shares is at $533.8 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock declined by 7.54% to $1.35. The market value of their outstanding shares is at $39.9 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 6.63% to $0.27. The market value of their outstanding shares is at $1.6 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock declined by 6.32% to $1.78. The company's market cap stands at $15.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined by 6.03% to $3.05. The market value of their outstanding shares is at $2.0 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock declined by 5.96% to $24.0. The market value of their outstanding shares is at $660.0 million. As per the news, the Q4 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

BCLI

DYAI

FGEN

IPSC

LENZ

SCNX

SHPH

Longevity Health Holdings, Inc. - Common Stock

XAGE

YCBD

12 Health Care Stocks Moving In Wednesday's After-Market Session

Akebia Therapeutics shares are trading lower after the company announced it commenced a public offering.

In addition, Akebia expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the Offering.

Offerings

Akebia Therapeutics Commences Public Offering; No Terms Disclosed

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/HNRG/earnings">a fourth-quarter sales miss.</a>
Hallador Energy reported quarterly earnings of 7 cents per share which beat the analyst consensus estimate of a loss of 13 cents per share. The company reported quarterly sales of $94.200 million which missed the analyst consensus estimate of $95.450 million.
Hallador Energy shares dipped 6.8% to $10.70 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Arlo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares tumbled 9.3% to $10.01 in pre-market trading after gaining 4% on Monday.</li>
<li>Ivanhoe Electric Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IE#NYSE">IE</a>) declined 6.9% to $5.92 in pre-market trading.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares declined 6% to $6.80 in pre-market trading after gaining 4% on Monday.</li>
<li>Resolute Holdings Management, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RHLD#NASDAQ">RHLD</a>) fell 4.8% to $42.05 in pre-market trading.</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) fell 4.1% to $6.75 in pre-market trading.</li>
<li>Kenon Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEN#NYSE">KEN</a>) fell 3.4% to $34.04 in pre-market trading after gaining 3% on Monday.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) fell 3.3% to $2.32 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) slipped 1.6% to $234.30 in pre-market trading. Tesla shares fell 4.8% on Monday after Mizuho cut its price target on the stock from $515 to $430. &nbsp;</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

ARLO

HNRG

RHLD

TSLA

VSTM

Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Akebia Therapeutics shares are trading higher after Piper Sandler raised its price target on the stock from $4 to $6.

<h3>Gainers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares rose 31.6% to $2.23 during Friday's regular session. The company's market cap stands at $485.4 million. The company's, Q4 earnings came out yesterday. </li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) stock rose 29.54% to $0.1. The company's market cap stands at $2.6 million. </li>
<li>Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) stock increased by 24.59% to $3.83. The market value of their outstanding shares is at $119.0 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) stock rose 20.52% to $4.17. The market value of their outstanding shares is at $33.6 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock moved upwards by 19.35% to $1.48. The market value of their outstanding shares is at $12.7 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) shares rose 17.88% to $0.81. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) shares declined by 29.6% to $0.88 during Friday's regular session. The market value of their outstanding shares is at $72.5 million. </li>
<li>NeueHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>) stock declined by 28.08% to $4.76. The company's market cap stands at $39.4 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares fell 23.29% to $5.93. The company's market cap stands at $7.8 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock fell 17.64% to $0.1. The company's market cap stands at $1.5 million. </li>
<li>Atlantic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLN#NASDAQ">ATLN</a>) shares decreased by 16.0% to $5.04. The market value of their outstanding shares is at $313.6 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares decreased by 15.56% to $0.57. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

AIFF

ATLN

BTMD

DWTX

NEUE

PLRZ

STRO

SYRS

12 Health Care Stocks Moving In Friday's Intraday Session

Piper Sandler analyst Allison Bratzel maintains Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Overweight and raises the price target from $4 to $6.

Piper Sandler Maintains Overweight on Akebia Therapeutics, Raises Price Target to $6

U.S. stocks were higher, with the Dow Jones index gaining around 1% on Friday.
Shares of Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) rose sharply during Friday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/25/03/44317455/semtech-shares-soar-after-better-than-expected-q4-results-details">fourth-quarter financial results</a>.
Semtech reported quarterly earnings of 40 cents per share, which beat the analyst consensus estimate of 32 cents by 25%. Quarterly revenue of $251 million beat the consensus estimate of $249.19 million and is up from $192.94 million from the same period last year.
Semtech shares jumped 12.7% to $36.86 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Radius Recycling, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDUS#NASDAQ">RDUS</a>) shares jumped 103% to $27.66 after the company disclosed a merger deal with Toyota Tsusho America, Inc. for $30.00 per share in cash.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) gained 37.7% to $21.86 after the company announced a warrant issuance agreement transaction with Amazon for 7,945,399 shares.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares climbed 26% to $8.73 on continued strength after the company on Thursday reported a 502% year-over-year increase in fourth-quarter bookings to $18.3 million.</li>
<li>Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) shares rose 25% to $69.08 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) gained 24% to $2.0950. HC Wainwright &amp; Co. analyst Ed Arce reiterated Akebia Therapeutics with a Buy and maintained a $7.5 price target.</li>
<li>Green Dot Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) rose 20.9% to $8.03.</li>
<li>REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) gained 17.5% to $7.70 following fourth-quarter earnings.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) jumped 17% to $10.22.</li>
<li>DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) rose 15% to $85.78 following better-than-expected quarterly financial results.</li>
<li>LexinFintech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) jumped 15% to $10.43.</li>
<li>Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) surged 15% to $2.61 following FY 2024 results.</li>
<li>Afya Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFYA#NASDAQ">AFYA</a>) gained 13.3% to $18.38 following upbeat earnings.</li>
<li>PagerDuty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) rose 12.7% to $17.59 after the company reported better-than-expected quarterly financial results and issued FY26 adjusted EPS guidance above estimates.</li>
<li>Futu Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) rose 12.5% to $120.97 after the company reported better-than-expected quarterly financial results.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) gained 10.6% to $9.85.</li>
<li>Crown Castle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) surged 8.5% to $101.50 following upbeat quarterly sales.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) rose 6.8% to $101.32.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) gained 6.7% to $335.48 after the company reported better-than-expected quarterly financial results.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 6.2% to $177.02. B of A Securities analyst Michael McGovern maintained Carvana with a Buy and lowered the price target from $270 to $220.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44325485/wall-streets-most-accurate-analysts-spotlight-on-3-real-estate-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>

AAOI

AFYA

BTBT

CVNA

DOCU

FUTU

GDOT

QBTS

RBRK

RDUS

RGNX

RGTI

SMTC

SOUN

ULTA

Semtech Posts Better-Than-Expected Earnings, Joins Rubrik, DocuSign, PagerDuty And Other Big Stocks Moving Higher On Friday

Akebia Therapeutics shares are trading lower after the company reported a Q4 GAAP EPS miss.

Press Releases

Akebia Therapeutics Announces Multiple Positive Business Updates

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Health Care

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Comments

Akebia Therapeutics

Vendite allo scoperto

Akebia Therapeutics (NASDAQ:AKBA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO